dMed Global, a full-service clinical contract research organization (CRO) headquartered in China, and Clinipace Incorporated, a full service clinical CRO with US headquarters, announced the merger of the two companies in April 2021. “Western biotech companies increasingly recognize their need for a strategic partner who can stay on the leading edge of fundamental changes in the global clinical landscape,” explains Dr. Lingshi Tan, Founder and Chairman of dMed Global and Global CEO for dMed/Clinipace. “We know that the drug development market in China is growing at greater than 20% a year per annum, and that is almost three times as fast as clinical research in the rest of the world,” says Jason Monteleone, Clinipace CEO who will serve as Chief Business and Strategy Officer for dMed/Clinipace. “We can partner with biotech companies, truly partner with them, be a solutions provider with them, and continue to provide the level of service they would expect out of a mid-size CRO but also bring them the size and scale of a little bit bigger business than both of us combined.”

Lingshi Tan Global CEO dMed/Clinipace		Jason Monteleone Chief Business & Strategy Officer dMed/Clinipace